Literature DB >> 16407544

Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies.

Patricia Szot1, Sylvia S White, J Lynne Greenup, James B Leverenz, Elaine R Peskind, Murray A Raskind.   

Abstract

In Alzheimer's disease (AD), there is a significant loss of locus ceruleus (LC) noradrenergic neurons. However, functional and anatomical evidence indicates that the remaining noradrenergic neurons may be compensating for the loss. Because the noradrenergic system plays an important role in learning and memory, it is important to determine whether compensation occurs in noradrenergic neurons in the LC and hippocampus of subjects with AD or a related dementing disorder, dementia with Lewy bodies (DLB). We observed profound neuronal loss in the LC in AD and DLB subjects with three major changes in the noradrenergic system consistent with compensation: (1) an increase in tyrosine hydroxylase (TH) mRNA expression in the remaining neurons; (2) sprouting of dendrites into peri-LC dendritic zone, as determined by alpha2-adrenoreceptors (ARs) and norepinephrine transporter binding sites; and (3) sprouting of axonal projections to the hippocampus as determined by alpha2-ARs. In AD and DLB subjects, the postsynaptic alpha1-ARs were normal to elevated. Expression of alpha1A- and alpha2A-AR mRNA in the hippocampus of AD and DLB subjects were not altered, but expression of alpha1D- and alpha2C-AR mRNA was significantly reduced in the hippocampus of AD and DLB subjects. Therefore, in AD and DLB subjects, there is compensation occurring in the remaining noradrenergic neurons, but there does appear to be a loss of specific AR in the hippocampus. Because changes in these noradrenergic markers in AD versus DLB subjects were similar (except neuronal loss and the increase in TH mRNA were somewhat greater in DLB subjects), the presence of Lewy bodies in addition to plaques and tangles in DLB subjects does not appear to further affect the noradrenergic compensatory changes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16407544      PMCID: PMC6674412          DOI: 10.1523/JNEUROSCI.4265-05.2006

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  88 in total

1.  Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine.

Authors:  Michael T Heneka; Fabian Nadrigny; Tommy Regen; Ana Martinez-Hernandez; Lucia Dumitrescu-Ozimek; Dick Terwel; Daniel Jardanhazi-Kurutz; Jochen Walter; Frank Kirchhoff; Uwe-Karsten Hanisch; Markus P Kummer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

Review 2.  Turning on the Light Within: Subcortical Nuclei of the Isodentritic Core and their Role in Alzheimer's Disease Pathogenesis.

Authors:  Panos Theofilas; Sara Dunlop; Helmut Heinsen; Lea Tenenholz Grinberg
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

3.  Amyloid beta peptide-(1-42) induces internalization and degradation of beta2 adrenergic receptors in prefrontal cortical neurons.

Authors:  Dayong Wang; Eunice Y Yuen; Yuan Zhou; Zhen Yan; Yang K Xiang
Journal:  J Biol Chem       Date:  2011-07-11       Impact factor: 5.157

4.  ADN-1184 a monoaminergic ligand with 5-HT(6/7) receptor antagonist activity: pharmacological profile and potential therapeutic utility.

Authors:  M Kołaczkowski; P Mierzejewski; P Bieńkowski; A Wesołowska; A Newman-Tancredi
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

5.  Pupillary Responses as a Biomarker of Early Risk for Alzheimer's Disease.

Authors:  Eric L Granholm; Matthew S Panizzon; Jeremy A Elman; Amy J Jak; Richard L Hauger; Mark W Bondi; Michael J Lyons; Carol E Franz; William S Kremen
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 6.  The hippocampus and cognitive impairments.

Authors:  E B Arushanyan; E V Beier
Journal:  Neurosci Behav Physiol       Date:  2008-10

7.  Neural reserve, neuronal density in the locus ceruleus, and cognitive decline.

Authors:  Robert S Wilson; Sukriti Nag; Patricia A Boyle; Loren P Hizel; Lei Yu; Aron S Buchman; Julie A Schneider; David A Bennett
Journal:  Neurology       Date:  2013-03-13       Impact factor: 9.910

8.  Genotype-independent decrease in plasma dopamine beta-hydroxylase activity in Alzheimer's disease.

Authors:  Maja Mustapic; Paola Presecki; Nela Pivac; Ninoslav Mimica; Patrick R Hof; Goran Simic; Vera Folnegovic-Smalc; Dorotea Muck-Seler
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-02-13       Impact factor: 5.067

9.  Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies.

Authors:  Kejal Kantarci; Tanis J Ferman; Bradley F Boeve; Stephen D Weigand; Scott Przybelski; Prashanthi Vemuri; Melissa E Murray; Melissa M Murray; Matthew L Senjem; Glenn E Smith; David S Knopman; Ronald C Petersen; Clifford R Jack; Joseph E Parisi; Dennis W Dickson
Journal:  Neurology       Date:  2012-07-25       Impact factor: 9.910

10.  Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans.

Authors:  E R Samuels; E Szabadi
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.